PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

China, Beijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital